SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

 

 

 

 

 FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of June 2026

 

TRINITY BIOTECH PLC

(Name of Registrant)

 

IDA Business Park

Bray, County. Wicklow, Ireland

 (Address of Principal Executive Office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F     Form 40-F       

 

 

This Form 6-K is being incorporated by reference into our Registration Statements on Form S-8 (File Nos. 333-182279, 333-195232 and 333-253070) and Form F-3 and (File Nos. 333-267160, 333-286020, 333-295842 and 333-280391).

 


 

 EXPLANATORY NOTE

 

On June 23, 2026, the Company announced the launch of Trinovium, a new subsidiary focused on bringing healthcare‑grade fluid technology to the AI data centre liquid cooling market. A copy of the press release is filed herewith as Exhibit 99.1


 

EXHIBIT INDEX

 

Exhibit

 

Description

99.1

 

Trinity Biotech Launches Trinovium to Bring Healthcare-Grade Fluid Technology to the Rapidly Growing Multi-Billion Dollar AI Data Center Liquid Cooling Market

 


 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

TRINITY BIOTECH PLC

 

 

 

Trinity Biotech plc

 

 

 

(Registrant)

 

 

 

 

 

 

By:

/s/ Paul Murphy

 

 

 

Paul Murphy

 

 

 

Interim Chief Financial Officer

 

 

Date: June 23, 2026

 

 

 


ATTACHMENTS / EXHIBITS

ATTACHMENTS / EXHIBITS

EXHIBIT 99.1